Showing results (281-290 of 324) with videos related to
Sort By:
Pageof 33
Pediatrics|January 27, 2010
Performance of 2004 American Heart Association recommendations for treatment of Kawasaki diseaseElizabeth S Yellen, Kimberlee Gauvreau, Masato Takahashi, et al.The Journal of Biological Chemistry|December 17, 2010
Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cellsJonathan L Coloff, Emily F Mason, Brian J Altman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancerLuca Gianni, Milvia Zambetti, Kim Clark, et al.The EMBO Journal|May 21, 2013
Eps8 controls dendritic spine density and synaptic plasticity through its actin-capping activityElisabetta Menna, Stefania Zambetti, Raffaella Morini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancerJosé Baselga, Milvia Zambetti, Antoni Llombart-Cussac, et al.Molecular Cancer Therapeutics|November 21, 2023
Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome BiogenesisPrahalathan Pichavaram, Carolyn M Jablonowski, Jie Fang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast CancerLuca Gianni, José Baselga, Wolfgang Eiermann, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapyLuca Gianni, José Baselga, Wolfgang Eiermann, et al.Breast Cancer Research : BCR|September 25, 2013
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersGiampaolo Bianchini, Lajos Pusztai, Thomas Karn, et al.Lancet (London, England)|February 2, 2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.Pageof 33